Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

Bibliography

• Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol1998;152:1259-69
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol2002;117:188-93
   PubMed Web of Science ®Google Scholar
• Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol2008;32:210-18
   PubMed Web of Science ®Google Scholar
• Wasag B, Debiec-Rychter M, Pauwels P, et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol2004;17:889-94
   PubMed Web of Science ®Google Scholar
• Pauls K, Merkelbach-Bruse S, Thal D, et al. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology2005;46:166-75
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch2001;438:1-12
   PubMed Web of Science ®Google Scholar
• Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene2004;23:3999-4006
   PubMed Web of Science ®Google Scholar
• Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate area. Cancer2005;103:821-9
   PubMed Web of Science ®Google Scholar
• Chan KH, Chan CW, Chow WH, et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol2006;12:2223-8
   PubMed Web of Science ®Google Scholar
• Goettscha W, Steffan D, Bosa S, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer2005;41:2868-72
   PubMed Web of Science ®Google Scholar
• Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer2005;117:289-93
   PubMed Web of Science ®Google Scholar
• Tzen CY, Wang JH, Huang YJ, et al. Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci2007;52:792-7
   PubMed Web of Science ®Google Scholar
• Agaimy A, Wuensch PH. Gastrointestinal stromal tumours in patients with other-type cancer: a mere coincidence or an etiological association? A study of 97 GIST cases. Z Gastroenterol2005;43:1025-30
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg2000;231:51-8
   PubMed Web of Science ®Google Scholar
• Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg1993;217:72-7
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol2002;33:466-77
   PubMed Web of Science ®Google Scholar
• De Pas T, Casali PG, Toma S, et al. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology2003;64:186-8
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol1999;6:645-50
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood2000;96:925-32
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene2001;20:5054-8
   PubMed Web of Science ®Google Scholar
• Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA2003;100:6706-11
   PubMed Web of Science ®Google Scholar
• Rubin BP, Antonescu CR, Scott-Browne JP, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res2005;65:6631-9
   PubMed Web of Science ®Google Scholar
• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol Mech Dis2008;3:557-86
   PubMed Web of Science ®Google Scholar
• Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res2004;64:5127-31
   PubMed Web of Science ®Google Scholar
• Bauer S, Yu LK, Demetri GD, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumour. Cancer Res2006;66:9153-61
   PubMed Web of Science ®Google Scholar
• Fumo G, Akin C, Metcalfe DD, et al. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood2004;103:1078-84
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Antonescu CR. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol2006;23:63-9
   PubMed Web of Science ®Google Scholar
• Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem2004;279:31655-63
   PubMed Web of Science ®Google Scholar
• Liu Y, Tseng M, Perdreau SA, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res2007;67:2685-92
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Hrychyk A, Merkelbach-Bruse S, et al. Association of platelet-derived growth factor receptor mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn2004;6:97-204
   Web of Science ®Google Scholar
• Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA2008;105:8387-92
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol2002;33:459-65
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med2006;130:1466-78
   PubMed Web of Science ®Google Scholar
• Yamaguchi U, Nakayama R, Honda K, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol2003;21:1688-97
   PubMed Web of Science ®Google Scholar
• Yamaguchi U, Nakayama R, Honda K, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol2008;26:4100-8
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kondo T, Seki K, et al. Pfetin as a prognostic biomarker of GIST revealed by proteomics. Clin Cancer Res2008;14:1707-17
   PubMed Web of Science ®Google Scholar
• Sabah M, Cummins R, Leader M, et al. Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol2004;17:1364-71
   PubMed Web of Science ®Google Scholar
• Nakamura N, Yamamoto H, Yao T, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol2005;36:828-37
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res1999;59:4297-300
   PubMed Web of Science ®Google Scholar
• Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol1999;154:53-60
   PubMed Web of Science ®Google Scholar
• Martín J, Poveda A, Llombart-Bosch A, et al. Spanish Group for Sarcoma Research. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol2005;23:6190-8
   PubMed Web of Science ®Google Scholar
• Andersson J, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology2006;130:1573-81
   PubMed Web of Science ®Google Scholar
• Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest2004;84:874-83
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol2006;23:91-102
   PubMed Web of Science ®Google Scholar
• Gold JS, van der Zwan SM, Gönen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol2007;14:134-42
   PubMed Web of Science ®Google Scholar
• El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. High resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer2000;27:387-91
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet2001;128:24-30
   PubMed Web of Science ®Google Scholar
• Gunawan B, von Heydebreck A, Sander B, et al. An oncogenic tree model in GISTs identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol2007;111:463-70
   Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med2001;344:1052-6
   PubMed Web of Science ®Google Scholar
• Van Glabbeke MM, Owzar K, Rankin C, et al. GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients. ASCO Annual Meeting Proceedings I; J Clin Oncol2007;25(Suppl):10004
   Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet2004;364:1127-34
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group; the Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer2006;42:1093-103
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol2006;24:4764-74
   PubMed Web of Science ®Google Scholar
• Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology2003;125:660-7
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol2005;23:5357-64
   PubMed Web of Science ®Google Scholar
• Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol2004;28:889-94
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol2007;25:1753-9
   PubMed Web of Science ®Google Scholar
• Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer2002;38:S60-5
   PubMed Web of Science ®Google Scholar
• Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie ‘addiction’ to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell2006;10:425-35
   PubMed Web of Science ®Google Scholar
• Liu Y, Tseng M, Perdreau SA, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res2007;67:2685-92
   PubMed Web of Science ®Google Scholar
• Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol2004;22:3813-25
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent N, et al. Molecular basis for sunitinib efficiency and future clinical development. Nat Rev Drug Discov2007;6:734-45
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol2006;24:4764-74
   PubMed Web of Science ®Google Scholar
• Wakai T, Kanda T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer2004;90:2059-61
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res2005;11:4182-90
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res2006;12:1743-9
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology2005;128:270-9
   PubMed Web of Science ®Google Scholar
• Agaram NP, Besmer P, Wong GC, et al. Pathologic and molecular heterogeneity in imatinib stable or imatinib responsive gastrointestinal stromal tumors. Clin Cancer Res2007;13:170-81
   PubMed Web of Science ®Google Scholar
• Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol2009;33:437-46
   PubMed Web of Science ®Google Scholar
• Judson I, Ma P, Peng B, et al. EORTC Soft Tissue and Bone Sarcoma Group. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. Cancer Chemother Pharmacol2005;55:379-86
   PubMed Web of Science ®Google Scholar
• Zalcberg JR, Verweij J, Paolo G, et al. for the EORTC Soft Tissue and Bone Sarcoma Group the Italian Sarcoma Group and the Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer2005;41:1751-7
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res2006;66:473-81
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res2006;12:6203-4
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Guida T, D'Attino R, et al. Sunitinib: bridging present and future cancer treatment. Ann Oncol2007;18:31-4
   Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. ASCO Annual Meeting Proceedings I; J Clin Oncol2006;24(Suppl):9502
   Web of Science ®Google Scholar
• Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res2008;14:5749-58
   PubMed Web of Science ®Google Scholar
• Weisberg E, Wright RD, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology2006;131:1734-42
   PubMed Web of Science ®Google Scholar
• Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib (SOR) in patients with imatinib (IM) and sunitinib (SU)-resistant gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. ASCO Annual Meeting Proceedings; J Clin Oncol2008;26(Suppl):10502
   Web of Science ®Google Scholar
• Von Mehren M, Reichardt P, Casali PG, et al. A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) – Study update. ASCO Annual Meeting Proceedings I; J Clin Oncol2007;25(Suppl):10023
   Google Scholar
• Reichardt P, Pink D, Lindner T, et al. A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. ASCO Annual Meeting Proceedings I; J Clin Oncol2005;23(Suppl):3016
   PubMed Web of Science ®Google Scholar
• Rossi F, Ehlers I, Agosti V, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA2006;103:12843-8
   PubMed Web of Science ®Google Scholar
• van Oosterom A, Reichardt P, Blay J, et al. A phase I/II trial of the oral mTOR-inhibitor everolimus and imatinib mesylate (IM) in patients with gastrointestinal stromal tumor refractory to IM: Study update. ASCO Annual Meeting Proceedings I; J Clin Oncol2005;23(Suppl):9033
   Google Scholar
• Steinert DM, Oyarzo M, Wang X, et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer2006;106:1617-23
   PubMed Web of Science ®Google Scholar
• Salto-Tellez M, Nga ME, Han HC, et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer2007;96:776-82
   PubMed Web of Science ®Google Scholar
• Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood2008;112:1886-93
   PubMed Web of Science ®Google Scholar
• Demetri GD, George S, Morgan JA, et al. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. J Clin Oncol2007;25:10024
   Google Scholar
• Sambol EB, Ambrosini G, Geha RC, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res2006;66:5858-66
   PubMed Web of Science ®Google Scholar
• Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer2008;47:853-9
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature2005;436:720-4
   PubMed Web of Science ®Google Scholar
• Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res2007;13:4874-81
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature2006;439:358-62
   PubMed Web of Science ®Google Scholar
• Sharp S, Workman P. Inhibitors of HSP90 molecular chaperone: current status. Adv Cancer Res2006;95:323-48
   PubMed Web of Science ®Google Scholar
• Braconi C, Bracci R, Bearzi I, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol2008;19:1293-8
   PubMed Web of Science ®Google Scholar
• Vasilcanu R, Vasilcanu D, Rosengren L, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene2008;27:1629-38
   PubMed Web of Science ®Google Scholar
• Economou MA, Andersson S, Vasilcanu D, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Acta Ophthalmol2008;86(Thesis 4):35-41
   PubMedGoogle Scholar
• Bümming P, Nilsson O, Ahlman H, et al. Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer2007;14:853-63
   PubMed Web of Science ®Google Scholar
• Nilsson O, Nilsson B, Arne G, et al. Expression of somatostatin receptors in primary GIST. Neuroendocrinology (In Press)
   Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer2008;8:755-68
   PubMed Web of Science ®Google Scholar
• Ischenko I, Seeliger H, Schaffer M, et al. Cancer stem cells: how can we target them? Curr Med Chem2008;15:3171-84
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst2008;100:672-9
   PubMed Web of Science ®Google Scholar